JP2002515868A5 - - Google Patents

Download PDF

Info

Publication number
JP2002515868A5
JP2002515868A5 JP1997533690A JP53369097A JP2002515868A5 JP 2002515868 A5 JP2002515868 A5 JP 2002515868A5 JP 1997533690 A JP1997533690 A JP 1997533690A JP 53369097 A JP53369097 A JP 53369097A JP 2002515868 A5 JP2002515868 A5 JP 2002515868A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997533690A
Other languages
English (en)
Japanese (ja)
Other versions
JP4210734B2 (ja
JP2002515868A (ja
Filing date
Publication date
Priority claimed from US08/821,739 external-priority patent/US20020168374A1/en
Application filed filed Critical
Publication of JP2002515868A publication Critical patent/JP2002515868A/ja
Publication of JP2002515868A5 publication Critical patent/JP2002515868A5/ja
Application granted granted Critical
Publication of JP4210734B2 publication Critical patent/JP4210734B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53369097A 1996-03-21 1997-03-21 Hla結合ペプチド及びその使用 Expired - Lifetime JP4210734B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1383396P 1996-03-21 1996-03-21
US60/013,833 1996-03-21
US08/821,739 1997-03-20
US08/821,739 US20020168374A1 (en) 1992-08-07 1997-03-20 Hla binding peptides and their uses
PCT/US1997/004451 WO1997034617A1 (en) 1996-03-21 1997-03-21 Hla binding peptides and their uses

Publications (3)

Publication Number Publication Date
JP2002515868A JP2002515868A (ja) 2002-05-28
JP2002515868A5 true JP2002515868A5 (enExample) 2004-12-02
JP4210734B2 JP4210734B2 (ja) 2009-01-21

Family

ID=26685309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53369097A Expired - Lifetime JP4210734B2 (ja) 1996-03-21 1997-03-21 Hla結合ペプチド及びその使用

Country Status (8)

Country Link
US (1) US20020168374A1 (enExample)
EP (1) EP0888120B1 (enExample)
JP (1) JP4210734B2 (enExample)
CN (1) CN1218404A (enExample)
AU (1) AU725550B2 (enExample)
BR (1) BR9708217A (enExample)
CA (1) CA2248659A1 (enExample)
WO (1) WO1997034617A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
WO1999003972A1 (en) * 1997-07-15 1999-01-28 Takara Shuzo Co., Ltd. Cytotoxic t lymphocytes
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
KR20010071848A (ko) * 1998-07-10 2001-07-31 교고 이또 Sart-1 유래의 종양 항원 펩티드
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP4776131B2 (ja) * 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
JP2003516131A (ja) * 1999-12-10 2003-05-13 エピミューン, インコーポレイテッド ペプチドおよび核酸組成物を使用する、p53に対する細胞性免疫応答の誘導
WO2001042270A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1244465A4 (en) * 1999-12-21 2005-01-12 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO ANTIGENS OF PROSTATE CANCER USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CA2421448A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
WO2002080848A2 (en) 2001-04-09 2002-10-17 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
EP1842911A4 (en) * 2005-01-25 2008-12-10 Nec Corp HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
CA2597373A1 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
KR101351195B1 (ko) * 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
JP2010001303A (ja) * 2009-08-17 2010-01-07 Pharmexa Inc Hla結合ペプチド及びその使用
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333670T2 (de) * 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン,インコーポレイティド Hla−a2.1結合ペプチドおよびそれらの使用
WO1995011255A1 (en) * 1993-10-19 1995-04-27 Ajinomoto Co., Inc. Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2002515868A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2001502170A5 (enExample)
JP2000501569A5 (enExample)